2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T5df,Radiation-induced oral mucositis (RIOM) is a severe complication of radiotherapy (RT) for head and neck cancers, impairing quality of life and treatment adherence. Low-level laser therapy (LLLT) shows promise for reducing RIOM severity, but operator-dependent devices limit practicality. This feasibility study assessed the safety and efficacy of a novel intraoral stent-based LLLT device designed for consistent laser delivery. This prospective, single-arm, multicenter study enrolled 15 patients receiving curative RT for head and neck cancers. The stent-based device delivered laser light to 43 oral cavity points at three wavelengths (670, 830, and 910 nm) during 20-min sessions, five times weekly. The primary end point was the incidence of Grade 3 or higher RIOM (WHO oral mucositis scale). Pain severity was a secondary end point (Numeric Pain Rating Scale [NPRS]). Grade 3 or higher RIOM occurred in 6.6% of patients, significantly lower than historical rates (30%-40%). No patients reported severe pain (NPRS ≥ 8). The device was well-tolerated with no adverse effects, and all patients completed RT as planned. The intraoral stent-based LLLT device is a safe and potentially effective intervention for reducing severe RIOM. Randomized trials are warranted to confirm these findings. This study was a prospective, single-arm feasibility trial and was not registered in a clinical trial registry, as it did not meet the criteria for mandatory registration at the time of its initiation.31:T790,ABSTRACTObjectivesRadiation‐induced oral mucositis (RIOM) is a severe complication of radiotherapy (RT) for head and neck cancers, impairing quality of life and treatment adherence. Low‐level laser therapy (LLLT) shows promise for reducing RIOM severity, but operator‐dependent devices limit practicality. This feasibility study assessed the safety and efficacy of a novel intraoral stent‐based LLLT device designed for consistent laser delivery.Materials and MethodsThis prospective, single‐arm, multicenter study enrolled 15 patients receiving curative RT for head and neck cancers. The stent‐based device delivered laser light to 43 oral cavity points at three wavelengths (670, 830, and 910 nm) during 20‐min sessions, five times weekly. The primary end point was the incidence of Grade 3 or higher RIOM (WHO oral mucositis scale). Pain severity was a secondary end point (Numeric Pain Rating Scale [NPRS]).ResultsGrade 3 or higher RIOM occurred in 6.6% of patients, significantly lower than historical rates (30%–40%). No patients reported severe pain (NPRS ≥ 8). The device was well‐tolerated with no adverse effects, and all patients completed RT as planned.ConclusionsThe intraoral stent‐based LLLT device is a safe and potentially effective intervention for reducing severe RIOM. Randomized trials are warranted to confirm these findings.Trial RegistrationThis study was a prospective, single‐arm feasibility trial and was not registered in a clinical trial registry, as it did not meet the criteria for mandatory registration at the time of its initiation.25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Head And Neck Cancer: condition Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Head And Neck Cancer (condition). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/condition/Head%20And%20Neck%20Cancer\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Conditions\",\"item\":\"https://www.reachrx.ai/hub/tag/condition\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Head And Neck Cancer\",\"item\":\"https://www.reachrx.ai/hub/tag/condition/Head%20And%20Neck%20Cancer\"}]}}"}}]],["$","$L2f",null,{"title":"Head And Neck Cancer: Research & Clinical Takeaways","description":"Discover peer-reviewed research on Head And Neck Cancer with concise clinician summaries and next-step guidance.","papers":[{"doi":"10.1016/j.ijid.2026.109067","pmid":"42604649","title":"HPV Vaccination and Risk of Head and Neck Cancers: A Large Real-World Cohort Study","journal_title":"International Journal of Infectious Diseases","journal_issn":"1201-9712","published_at":"2026-08-16T00:00:00.000Z","url":"https://doi.org/10.1016/j.ijid.2026.109067","source_score":24,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-23T07:33:02.008Z","updated_at":"2026-08-23T07:33:02.008Z","tags":[{"paper_doi":"10.1016/j.ijid.2026.109067","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.ijid.2026.109067","tag_type":"category","value":"Infectious Diseases","value_numeric":null},{"paper_doi":"10.1016/j.ijid.2026.109067","tag_type":"condition","value":"Head And Neck Cancer","value_numeric":null},{"paper_doi":"10.1016/j.ijid.2026.109067","tag_type":"condition","value":"Oropharyngeal Squamous Cell Carcinoma","value_numeric":null},{"paper_doi":"10.1016/j.ijid.2026.109067","tag_type":"generic","value":"human papillomavirus vaccine","value_numeric":null},{"paper_doi":"10.1016/j.ijid.2026.109067","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1016/j.ijid.2026.109067","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1016/j.ijid.2026.109067","tag_type":"modality","value":"HPV Vaccine","value_numeric":null},{"paper_doi":"10.1016/j.ijid.2026.109067","tag_type":"sample_size","value":"n=1433260","value_numeric":1433260},{"paper_doi":"10.1016/j.ijid.2026.109067","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.ijid.2026.109067","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1016/j.ijid.2026.109067","tag_type":"warning","value":"Matching on age, sex, and comorbidities may not fully control for behavioral confounders such as smoking history or number of sexual partners, which are strong HNC risk factors.","value_numeric":null},{"paper_doi":"10.1016/j.ijid.2026.109067","tag_type":"warning","value":"No specific HPV vaccine type (e.g., bivalent, quadrivalent, 9-valent) is identified in the abstract; effectiveness may vary by formulation.","value_numeric":null},{"paper_doi":"10.1016/j.ijid.2026.109067","tag_type":"warning","value":"The absolute event counts are low (40 vaccinated vs. 130 controls), so subgroup HRs—particularly for OPSCC—should be interpreted cautiously due to wide potential confidence intervals not reported in the abstract.","value_numeric":null}],"summaries":{"what_studied":"This retrospective cohort study evaluated whether HPV vaccination reduces head and neck cancer (HNC) incidence in a U.S. real-world population of 1,433,260 matched individuals (ages 9–45), comparing 716,630 vaccinated persons to 716,630 unvaccinated controls, matched on age, sex, and comorbidities, across 66 U.S. healthcare organizations.","key_result":"HPV vaccination was associated with a 68% lower risk of HNC overall (40 vs. 130 cases; HR 0.315), with the strongest effect for oropharyngeal squamous cell carcinoma (HR 0.087, ~91% reduction); risk reduction was also seen in ages 9–26 (HR 0.323) and persisted 5–13 years post-vaccination.","limitations":"Retrospective observational design limits causal inference; residual confounding (e.g., sexual behavior, smoking) cannot be excluded despite matching; HNC case counts are small (40 vs. 130), which may limit precision of subgroup estimates.","practice_takeaway":"These real-world data strongly support HPV vaccination—especially in patients aged 9–26—as a meaningful strategy to reduce oropharyngeal and other head and neck cancers. Clinicians should prioritize timely HPV immunization and counsel patients on its long-lasting protective effect."}},{"doi":"10.1001/jamaoto.2026.2045","pmid":"42530947","title":"Circulating Tumor DNA in Head and Neck Cancer","journal_title":"JAMA Otolaryngology–Head & Neck Surgery","journal_issn":"2168-6181","published_at":"2026-07-30T00:00:00.000Z","url":"https://doi.org/10.1001/jamaoto.2026.2045","source_score":10,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-04T18:17:40.444Z","updated_at":"2026-08-04T18:17:40.444Z","tags":[{"paper_doi":"10.1001/jamaoto.2026.2045","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamaoto.2026.2045","tag_type":"category","value":"Surgery","value_numeric":null},{"paper_doi":"10.1001/jamaoto.2026.2045","tag_type":"condition","value":"Head And Neck Cancer","value_numeric":null},{"paper_doi":"10.1001/jamaoto.2026.2045","tag_type":"condition","value":"Nasopharyngeal Cancer","value_numeric":null},{"paper_doi":"10.1001/jamaoto.2026.2045","tag_type":"condition","value":"Oropharyngeal Cancer","value_numeric":null},{"paper_doi":"10.1001/jamaoto.2026.2045","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1001/jamaoto.2026.2045","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1001/jamaoto.2026.2045","tag_type":"modality","value":"Circulating Tumor DNA","value_numeric":null},{"paper_doi":"10.1001/jamaoto.2026.2045","tag_type":"modality","value":"Liquid Biopsy","value_numeric":null},{"paper_doi":"10.1001/jamaoto.2026.2045","tag_type":"study_design","value":"Narrative Review","value_numeric":null},{"paper_doi":"10.1001/jamaoto.2026.2045","tag_type":"warning","value":"Full text was inaccessible due to a security verification page; all extracted content is based solely on the abstract. Specific trial names, patient numbers, and quantitative results could not be confirmed.","value_numeric":null},{"paper_doi":"10.1001/jamaoto.2026.2045","tag_type":"warning","value":"No sample size is reported — this is a review article with no primary patient cohort.","value_numeric":null},{"paper_doi":"10.1001/jamaoto.2026.2045","tag_type":"warning","value":"Study design is tagged as 'Narrative Review' based on abstract language; it is described as a review by a society committee, which may carry editorial or consensus characteristics not fully captured by this label.","value_numeric":null}],"summaries":{"what_studied":"A review conducted by the American Head and Neck Society evaluating the current and emerging utility of circulating tumor DNA (ctDNA) — including oncogenic viral DNA from HPV and EBV — as a biomarker in head and neck cancers, focusing on treatment response monitoring, minimal residual disease (MRD) detection, and precision oncology applications.","key_result":"Liquid biopsy targeting viral ctDNA shows promise as a diagnostic and surveillance biomarker across head and neck cancer subtypes, particularly HPV-associated oropharynx and EBV-associated nasopharynx cancers; however, routine clinical use is limited by test variability and the risks of inaccurate results.","limitations":"Full text was inaccessible; summary is based on abstract only. The review does not appear to include primary data or quantitative outcomes. Conclusions rely on ongoing trials whose results are not yet available.","practice_takeaway":"ctDNA (especially viral ctDNA) is not yet standard of care in head and neck oncology — clinicians should view it as investigational and await results from ongoing clinical trials before using it to drive treatment decisions. Test variability and the implications of false results must be weighed carefully."}},{"doi":"10.1200/jco-25-01546","pmid":"41604598","title":"Efficacy and Safety of Ultra-Low-Dose Immunotherapy in Relapsed Refractory Solid Tumors: Phase III Superiority Randomized Trial (DELII)","journal_title":"Journal of Clinical Oncology","journal_issn":"0732-183X","published_at":"2026-01-28T00:00:00.000Z","url":"https://doi.org/10.1200/jco-25-01546","source_score":99,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-20T13:23:31.296Z","updated_at":"2026-05-20T13:23:31.296Z","tags":[{"paper_doi":"10.1200/jco-25-01546","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1200/jco-25-01546","tag_type":"brand","value":"Opdivo","value_numeric":null},{"paper_doi":"10.1200/jco-25-01546","tag_type":"category","value":"Oncology","value_numeric":null},{"paper_doi":"10.1200/jco-25-01546","tag_type":"condition","value":"Head And Neck Cancer","value_numeric":null},{"paper_doi":"10.1200/jco-25-01546","tag_type":"condition","value":"Lung Cancer","value_numeric":null},{"paper_doi":"10.1200/jco-25-01546","tag_type":"condition","value":"Solid Tumors","value_numeric":null},{"paper_doi":"10.1200/jco-25-01546","tag_type":"generic","value":"docetaxel","value_numeric":null},{"paper_doi":"10.1200/jco-25-01546","tag_type":"generic","value":"nivolumab","value_numeric":null},{"paper_doi":"10.1200/jco-25-01546","tag_type":"generic","value":"paclitaxel","value_numeric":null},{"paper_doi":"10.1200/jco-25-01546","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1200/jco-25-01546","tag_type":"level_of_evidence","value":"1","value_numeric":null},{"paper_doi":"10.1200/jco-25-01546","tag_type":"modality","value":"Chemotherapy","value_numeric":null},{"paper_doi":"10.1200/jco-25-01546","tag_type":"modality","value":"Immune Checkpoint Inhibitor","value_numeric":null},{"paper_doi":"10.1200/jco-25-01546","tag_type":"sample_size","value":"n=500","value_numeric":500},{"paper_doi":"10.1200/jco-25-01546","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1200/jco-25-01546","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1200/jco-25-01546","tag_type":"warning","value":"No PD-L1 or other predictive biomarker subgroup data were reported in the abstract; the OS benefit may be driven by a biomarker-enriched subset.","value_numeric":null},{"paper_doi":"10.1200/jco-25-01546","tag_type":"warning","value":"The 'impact_flag: practice_changing' designation reflects the Phase III superiority design and statistically significant OS benefit, but the modest absolute gain (~1.2 months) and lack of PFS benefit warrant cautious interpretation.","value_numeric":null},{"paper_doi":"10.1200/jco-25-01546","tag_type":"warning","value":"The paper is published with a 2026-01-28 date but the DOI resolves to a JCO article; the trial appears to be a real Phase III trial (DELII), but clinicians should verify final published data as this may be an ahead-of-print version.","value_numeric":null},{"paper_doi":"10.1200/jco-25-01546","tag_type":"warning","value":"Tumor histology mix (predominantly head & neck and lung) limits applicability to other solid tumor types not well represented in this trial.","value_numeric":null}],"summaries":{"what_studied":"Phase III randomized superiority trial (DELII) comparing ultra-low-dose nivolumab (20 mg IV q2w) vs. standard chemotherapy (docetaxel or paclitaxel) in 500 adults with relapsed/refractory advanced solid tumors (ECOG 0–1, ≥1 prior line), enrolled June 2020–February 2024; primary endpoint was overall survival (OS).","key_result":"Median OS was significantly longer with ultra-low-dose nivolumab vs. chemotherapy (5.88 vs. 4.70 months; HR 0.80 [95% CI 0.66–0.97]; P=.022); 1-year OS 27.3% vs. 16.9%. PFS was similar between arms (2.04 vs. 2.09 months; HR 1.03; P=.77). Grade ≥3 treatment-related adverse events were less frequent with nivolumab (42.5% vs. 60.8%; P<.001), and QoL favored nivolumab.","limitations":"- Heterogeneous tumor types (52% head & neck, 36% lung) limit generalizability to other cancers.\n- No biomarker-stratified analysis (e.g., PD-L1 expression) reported, making it unclear which subgroups drive the OS benefit.\n- Median OS benefit is modest (~1.2 months), and PFS did not differ, raising questions about the mechanism of late survival separation.","practice_takeaway":"Ultra-low-dose nivolumab (20 mg q2w) may be a viable alternative to second-line chemotherapy in pretreated solid tumors, offering a small but significant OS advantage and a better toxicity and QoL profile. Clinicians should consider this option especially in resource-limited settings where standard ICI dosing costs are prohibitive."}},{"doi":"10.1002/lsm.70069","pmid":"41058057","title":"Feasibility Study of a Novel Stent‐Based Low‐Level Laser Therapy Device for Reducing Severe Radiation‐Induced Oral Mucositis","journal_title":"Lasers in Surgery and Medicine","journal_issn":"0196-8092","published_at":"2025-10-08T00:00:00.000Z","url":"https://doi.org/10.1002/lsm.70069","source_score":2,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2025-10-09","doi":"10.1002/lsm.70069","days":"7","issn":"0196-8092","rank":"10","field":"Clinical Medicine","score":"2","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1002/lsm.70069","title":"Feasibility Study of a Novel Stent-Based Low-Level Laser Therapy Device for Reducing Severe Radiation-Induced Oral Mucositis.","journal":"Lasers in surgery and medicine","methods":"","results":"Grade 3 or higher RIOM occurred in 6.6% of patients, significantly lower than historical rates (30%-40%). No patients reported severe pain (NPRS ≥ 8). The device was well-tolerated with no adverse effects, and all patients completed RT as planned.","abstract":"$30","keywords":["feasibility studies","head and neck neoplasms","low‐level light therapy","oral mucositis","radiotherapy"],"pubmed_id":"41058057","conclusions":"","publication_date":"2025-10-08T00:00:00"},"crossref":{"DOI":"10.1002/lsm.70069","URL":"https://doi.org/10.1002/lsm.70069","ISSN":["0196-8092","1096-9101"],"link":[{"URL":"https://onlinelibrary.wiley.com/doi/pdf/10.1002/lsm.70069","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Feasibility Study of a Novel Stent‐Based Low‐Level Laser Therapy Device for Reducing Severe Radiation‐Induced Oral Mucositis"],"author":[{"given":"Jong Yun","family":"Baek","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Samsung Medical Center Sungkyunkwan University School of Medicine Seoul South Korea"}]},{"given":"Kyungmi","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Samsung Medical Center Sungkyunkwan University School of Medicine Seoul South Korea"}]},{"given":"Tae Hoon","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Samsung Medical Center Sungkyunkwan University School of Medicine Seoul South Korea"}]},{"given":"Sung Uk","family":"Lee","sequence":"additional","affiliation":[{"name":"Proton Therapy Center, Research Institute and Hospital National Cancer Center Goyang‐si South Korea"}]},{"given":"Sung Ho","family":"Moon","sequence":"additional","affiliation":[{"name":"Proton Therapy Center, Research Institute and Hospital National Cancer Center Goyang‐si South Korea"}]},{"given":"In Young","family":"Jo","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Soonchunhyang University Hospital Cheonan South Korea"}]},{"given":"Keun‐Yong","family":"Eom","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Seoul National University Bundang Hospital, Seoul National University College of Medicine Seongnam South Korea"}]},{"given":"Dongryul","family":"Oh","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Samsung Medical Center Sungkyunkwan University School of Medicine Seoul South Korea"}]}],"issued":{"date-parts":[[2025,10,7]]},"member":"311","prefix":"10.1002","source":"Crossref","volume":null,"archive":["Portico"],"created":{"date-time":"2025-10-08T04:21:53Z","timestamp":1759897313000,"date-parts":[[2025,10,8]]},"indexed":{"date-time":"2025-10-08T04:42:18Z","timestamp":1759898538373,"date-parts":[[2025,10,8]]},"license":[{"URL":"http://creativecommons.org/licenses/by-nc/4.0/","start":{"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000,"date-parts":[[2025,10,7]]},"delay-in-days":0,"content-version":"vor"}],"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://onlinelibrary.wiley.com/doi/10.1002/lsm.70069"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","order":0,"value":"2025-04-16"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","order":2,"value":"2025-09-24"},{"name":"published","group":{"name":"publication_history","label":"Publication History"},"label":"Published","order":3,"value":"2025-10-07"}],"deposited":{"date-time":"2025-10-08T04:21:56Z","timestamp":1759897316000,"date-parts":[[2025,10,8]]},"issn-type":[{"type":"print","value":"0196-8092"},{"type":"electronic","value":"1096-9101"}],"published":{"date-parts":[[2025,10,7]]},"publisher":"Wiley","reference":[{"DOI":"10.4143/crt.2023.447","key":"e_1_2_10_2_1","year":"2023","issue":null,"author":"Kang M. J.","volume":"55","first-page":"385","unstructured":null,"article-title":"Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2020","journal-title":"Cancer Research and Treatment","doi-asserted-by":"crossref"},{"DOI":"10.1038/s41415-022-5151-4","key":"e_1_2_10_3_1","year":"2022","issue":null,"author":"Creaney G.","volume":"233","first-page":"787","unstructured":null,"article-title":"Head and Neck Cancer in the UK: What Was the Stage Before COVID‐19? UK Cancer Registries Analysis (2011–2018)","journal-title":"British Dental Journal","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(21)01550-6","key":"e_1_2_10_4_1","year":"2021","issue":null,"author":"Mody M. D.","volume":"398","first-page":"2289","unstructured":null,"article-title":"Head and Neck Cancer","journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0167-8140(02)00404-8","key":"e_1_2_10_5_1","year":"2003","issue":null,"author":"Trotti A.","volume":"66","first-page":"253","unstructured":null,"article-title":"Mucositis Incidence, Severity and Associated Outcomes in Patients With Head and Neck Cancer Receiving Radiotherapy With or Without Chemotherapy: A Systematic Literature Review","journal-title":"Radiotherapy and Oncology","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamanetworkopen.2023.37265","key":"e_1_2_10_6_1","year":"2023","issue":null,"author":"Iovoli A. J.","volume":"6","first-page":null,"unstructured":null,"article-title":"Severe Oral Mucositis After Intensity‐Modulated Radiation Therapy for Head and Neck Cancer","journal-title":"JAMA Network Open","doi-asserted-by":"crossref"},{"DOI":"10.1002/cncr.21622","key":"e_1_2_10_7_1","year":"2006","issue":null,"author":"Vera‐Llonch M.","volume":"106","first-page":"329","unstructured":null,"article-title":"Oral Mucositis in Patients Undergoing Radiation Treatment for Head and Neck Carcinoma","journal-title":"Cancer","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00520-009-0771-7","key":"e_1_2_10_8_1","year":"2010","issue":null,"author":"Cheng K. K. F.","volume":"18","first-page":"1477","unstructured":null,"article-title":"Severe Oral Mucositis Associated With Cancer Therapy: Impact on Oral Functional Status and Quality of Life","journal-title":"Supportive Care in Cancer","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00520-016-3152-z","key":"e_1_2_10_9_1","year":"2016","issue":null,"author":"Zecha J. A. E. M.","volume":"24","first-page":"2781","unstructured":null,"article-title":"Low Level Laser Therapy/Photobiomodulation in the Management of Side Effects of Chemoradiation Therapy in Head and Neck Cancer: Part 1: Mechanisms of Action, Dosimetric, and Safety Considerations","journal-title":"Supportive Care in Cancer","doi-asserted-by":"crossref"},{"DOI":null,"key":"e_1_2_10_10_1","year":"2010","issue":null,"author":"Clarkson J. E.","volume":null,"first-page":null,"unstructured":null,"article-title":"Interventions for Treating Oral Mucositis for Patients With Cancer Receiving Treatment","journal-title":"Cochrane Database of Systematic Reviews","doi-asserted-by":null},{"DOI":null,"key":"e_1_2_10_11_1","year":"2011","issue":null,"author":"Worthington H. V.","volume":null,"first-page":null,"unstructured":null,"article-title":"Interventions for Preventing Oral Mucositis for Patients With Cancer Receiving Treatment","journal-title":"Cochrane Database of Systematic Reviews","doi-asserted-by":null},{"DOI":"10.1007/s00520-011-1202-0","key":"e_1_2_10_12_1","year":"2011","issue":null,"author":"Bjordal J. M.","volume":"19","first-page":"1069","unstructured":null,"article-title":"A Systematic Review With Meta‐Analysis of the Effect of Low‐Level Laser Therapy (LLLT) in Cancer Therapy‐Induced Oral Mucositis","journal-title":"Supportive Care in Cancer","doi-asserted-by":"crossref"},{"DOI":"10.1097/CCO.0b013e328352eaa3","key":"e_1_2_10_13_1","year":"2012","issue":null,"author":"Bensadoun R. J.","volume":"24","first-page":"363","unstructured":null,"article-title":"Low‐Level Laser Therapy in the Prevention and Treatment of Cancer Therapy‐Induced Mucositis: 2012 State of the Art Based on Literature Review and Meta‐Analysis","journal-title":"Current Opinion in Oncology","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00520-012-1605-6","key":"e_1_2_10_14_1","year":"2013","issue":null,"author":"Migliorati C.","volume":"21","first-page":"333","unstructured":null,"article-title":"Systematic Review of Laser and Other Light Therapy for the Management of Oral Mucositis in Cancer Patients","journal-title":"Supportive Care in Cancer","doi-asserted-by":"crossref"},{"DOI":"10.1371/journal.pone.0107418","key":"e_1_2_10_15_1","year":"2014","issue":null,"author":"Oberoi S.","volume":"9","first-page":null,"unstructured":null,"article-title":"Effect of Prophylactic Low Level Laser Therapy on Oral Mucositis: A Systematic Review and Meta‐Analysis","journal-title":"PLoS One","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00520-019-04890-2","key":"e_1_2_10_16_1","year":"2019","issue":null,"author":"Zadik Y.","volume":"27","first-page":"3969","unstructured":null,"article-title":"Systematic Review of Photobiomodulation for the Management of Oral Mucositis in Cancer Patients and Clinical Practice Guidelines","journal-title":"Supportive Care in Cancer","doi-asserted-by":"crossref"},{"DOI":"10.1007/s10103-023-03940-w","key":"e_1_2_10_17_1","year":"2023","issue":"1","author":"Potrich A. R.","volume":"39","first-page":"1","unstructured":null,"article-title":"Impact of Photobiomodulation for Prevention of Oral Mucositis on the Quality of Life of Patients With Head and Neck Cancer: A Systematic Review","journal-title":"Lasers in Medical Science","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00520-023-08105-7","key":"e_1_2_10_18_1","year":"2023","issue":null,"author":"Cruz A. R.","volume":"31","first-page":"645","unstructured":null,"article-title":"Efficacy of Photobiomodulation in the Treatment of Oral Mucositis in Patients Undergoing Antineoplastic Therapy: Systematic Review and Meta‐Analysis","journal-title":"Supportive Care in Cancer","doi-asserted-by":"crossref"},{"DOI":"10.5005/jp-journals-10024-3277","key":"e_1_2_10_19_1","year":"2022","issue":null,"author":"Carli J. P.","volume":"23","first-page":"31","unstructured":null,"article-title":"Low‐Level Laser Therapy in the Management of Oral Mucositis Induced by Radiotherapy: A Randomized Double‐Blind Clinical Trial","journal-title":"Journal of Contemporary Dental Practice","doi-asserted-by":"crossref"},{"DOI":"10.1002/cncr.33100","key":"e_1_2_10_20_1","year":"2020","issue":null,"author":"Elad S.","volume":"126","first-page":"4423","unstructured":null,"article-title":"MASCC/ISOO Clinical Practice Guidelines for the Management of Mucositis Secondary to Cancer Therapy","journal-title":"Cancer","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.radonc.2013.08.010","key":"e_1_2_10_21_1","year":"2013","issue":null,"author":"Antunes H. S.","volume":"109","first-page":"297","unstructured":null,"article-title":"Phase III Trial of Low‐Level Laser Therapy to Prevent Oral Mucositis in Head and Neck Cancer Patients Treated With Concurrent Chemoradiation","journal-title":"Radiotherapy and Oncology","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.oraloncology.2017.05.018","key":"e_1_2_10_22_1","year":"2017","issue":null,"author":"Antunes H. S.","volume":"71","first-page":"11","unstructured":null,"article-title":"Long‐Term Survival of a Randomized Phase III Trial of Head and Neck Cancer Patients Receiving Concurrent Chemoradiation Therapy With or Without Low‐Level Laser Therapy (LLLT) to Prevent Oral Mucositis","journal-title":"Oral Oncology","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00520-018-4046-z","key":"e_1_2_10_23_1","year":"2018","issue":null,"author":"Brandão T. B.","volume":"26","first-page":"2417","unstructured":null,"article-title":"Locally Advanced Oral Squamous Cell Carcinoma Patients Treated With Photobiomodulation for Prevention of Oral Mucositis: Retrospective Outcomes and Safety Analyses","journal-title":"Supportive Care in Cancer","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.oraloncology.2016.01.005","key":"e_1_2_10_24_1","year":"2016","issue":null,"author":"Sonis S. T.","volume":"54","first-page":"7","unstructured":null,"article-title":"Could the Biological Robustness of Low Level Laser Therapy (Photobiomodulation) Impact Its Use in the Management of Mucositis in Head and Neck Cancer Patients","journal-title":"Oral Oncology","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.oraloncology.2019.04.004","key":"e_1_2_10_25_1","year":"2019","issue":null,"author":"Pauli Paglioni M.","volume":"93","first-page":"21","unstructured":null,"article-title":"Tumor Safety and Side Effects of Photobiomodulation Therapy Used for Prevention and Management of Cancer Treatment Toxicities. A Systematic Review","journal-title":"Oral Oncology","doi-asserted-by":"crossref"}],"short-title":[],"update-policy":"https://doi.org/10.1002/crossmark_policy","alternative-id":["10.1002/lsm.70069"],"article-number":"lsm.70069","content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Lasers in Surgery and Medicine"],"reference-count":24,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,10,7]]},"references-count":24,"short-container-title":["Lasers Surg Med"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1002/lsm.70069","is_oa":true,"title":"Feasibility Study of a Novel Stent‐Based Low‐Level Laser Therapy Device for Reducing Severe Radiation‐Induced Oral Mucositis","updated":"2025-10-10T00:14:49+00:00","published_date":"2025-10-07","best_oa_location":{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/lsm.70069","pmh_id":null,"url_for_pdf":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/lsm.70069","url_for_landing_page":"https://doi.org/10.1002/lsm.70069"}}},"created_at":"2025-10-13T07:32:37.233Z","updated_at":"2025-10-15T07:01:11.375Z","tags":[{"paper_doi":"10.1002/lsm.70069","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1002/lsm.70069","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1002/lsm.70069","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1002/lsm.70069","tag_type":"condition","value":"Head And Neck Cancer","value_numeric":null},{"paper_doi":"10.1002/lsm.70069","tag_type":"condition","value":"Radiation-Induced Oral Mucositis","value_numeric":null},{"paper_doi":"10.1002/lsm.70069","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1002/lsm.70069","tag_type":"level_of_evidence","value":"6","value_numeric":null},{"paper_doi":"10.1002/lsm.70069","tag_type":"modality","value":"Photobiomodulation","value_numeric":null},{"paper_doi":"10.1002/lsm.70069","tag_type":"sample_size","value":"n=15","value_numeric":15},{"paper_doi":"10.1002/lsm.70069","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1002/lsm.70069","tag_type":"study_design","value":"Prospective Single-Arm Trial","value_numeric":null},{"paper_doi":"10.1002/lsm.70069","tag_type":"warning","value":"Design classification is approximate; this was a prospective, single‑arm feasibility study.","value_numeric":null},{"paper_doi":"10.1002/lsm.70069","tag_type":"warning","value":"Efficacy comparisons rely on historical rates rather than a concurrent control group.","value_numeric":null},{"paper_doi":"10.1002/lsm.70069","tag_type":"warning","value":"The report states lower rates versus historical controls but does not provide statistical testing details.","value_numeric":null}],"summaries":{"what_studied":"Prospective, single‑arm, multicenter feasibility study (n=15) in adults receiving curative head and neck radiotherapy, testing an intraoral stent‑based low‑level laser therapy that delivered light to 43 oral sites (670, 830, 910 nm) for 20 minutes, five times weekly from week 2 of RT through completion (study period September 2023–May 2024). The primary endpoint was incidence of WHO grade ≥3 radiation‑induced oral mucositis; pain (Numeric Pain Rating Scale) was secondary, with a final assessment 4 weeks post‑RT.","key_result":"Grade ≥3 mucositis occurred in 1/15 patients (6.6%) versus historical rates of 30%–40%. No patient reported severe pain (NPRS ≥8); four reported pain up to 4, all completed RT (five had 1–5‑day interruptions), and no device‑related adverse effects were observed.","limitations":"Single‑arm design with comparisons to historical controls, without a concurrent comparator. Small sample size (n=15) limits precision. Short follow‑up (final evaluation 4 weeks post‑RT) and no photographic documentation.","practice_takeaway":"Stent‑based photobiomodulation was feasible, well tolerated, and associated with a low rate of severe mucositis in this small cohort. Continue using LLLT per guidelines where applicable, and await randomized trials before adopting this stent device broadly."}}],"initialOffset":4,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"condition","value":"Head And Neck Cancer"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Conditions","href":"/hub/tag/condition"},{"name":"Head And Neck Cancer"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"condition","hub_tag_value":"Head And Neck Cancer"}}}]]

Papers